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Several studies have reported high rates of alexithymia in drug-dependent individuals, but
supporting evidence attests association between alexithymia and a variety of psychiatric
disorders, raising doubts about its specificity. Moreover, controversies are emerging
about alexithymia assessment: self-report measures present shortcomings with respect
to discriminant validity and reliability. As regards treatment for substance use disorders
(SUDs), alexithymia has been linked to poorer outcomes, but the results are inconsistent.
The aim of the present study is to investigate alexithymia in substance-dependent young
adults by examining: (a) the specificity of alexithymia in drug-dependent inpatients,
compared to healthy individuals and patients with psychiatric disorders (behavioral and
emotional disorders) and (b) the predictivity of alexithymia in determining treatment
outcomes in terms of relapses, drop-outs from treatment and the rate of relapse per
month of treatment. Two studies were conducted to fulfill these aims: Study 1 and
Study 2. Study 1 involved 90 late adolescents, aged 17–21. To fulfill the first aim,
30 inpatients diagnosed with SUD were compared with 30 healthy controls and 30
individuals referred to an outpatient neuropsychiatric unit (a). The participants completed
the Toronto Alexithymia Scale−20 (TAS-20) and the Symptom Checklist-90-Revised
(SCL-90-R). The results indicated that both clinical groups reported higher TAS-20 scores
than the non-clinical subjects, but they did not differ from each other (a); moreover,
a large correlation was detected between alexithymia and depressive symptoms, as
assessed by the SCL-90-R. Study 2 involved 55 inpatients with SUD recruited in a
therapeutic community. The participants completed the TAS-20, and clinicians filled out
the Observer Alexithymia Scale (OAS). No association was found between self-report
and observational measures. Neither self-reported nor observed alexithymia predicted
the number of relapses, drop-out from treatment, or the rate of relapses per month
of treatment (b). When the interaction with gender was explored, the global score of
alexithymia and the “Distant” OAS subscale predicted the number rate relapses only in
males. The TAS-20 did not discriminate between the clinical groups. The limited ability
of both observed and self-reported measures in predicting treatment outcome raises
questions on the specificity of alexithymia among the substance-dependent inpatient
population.
Keywords: alexithymia, substance use disorder, young adulthood, treatment outcome, 20 Item -Toronto
Alexithymia Scale
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THEORETICAL BACKGROUND
Alexithymia refers to the psychological dysfunctional trait of
having no words to express emotions or feelings (Sifneos, 1973).
It is a multidimensional construct comprising emotional and
cognitive components: difficulties in identifying and describing
feelings as well as in differentiating somatic sensations and
feelings, lack of fantasy, and imagination and an externally
oriented cognitive style (Nemiah and Sifneos, 1970; Nemiah
et al., 1976; Taylor et al., 1997). Interestingly, the relevance
of alexithymia has grown exponentially in the last decades;
it is currently considered a relevant concept for a range of
psychological and physical disorders (Taylor et al., 1997; Taylor
and Bagby, 2004), and attention is paid to its relationships with
other constructs, such as emotional intelligence, negative affect,
and its role in predicting treatment outcomes (Morie et al., 2016).
Alexithymic Traits in Drug-Dependent
Individuals
Vast research has suggested that alexithymia is quite common in
patients with substance use disorders (SUDs) (Handelsman et al.,
2000; Speranza et al., 2004; Cleland et al., 2005; De Rick and
Vanheule, 2006; Oyefeso et al., 2008; Lindsay and Ciarrochi, 2009;
Thorberg et al., 2009; Torrado et al., 2013; Nehra et al., 2014).
When considering alexithymia as a categorical variable, while
rates in the general adult population range between 6 and 17%
(Hintikka et al., 2001; Kokkonen et al., 2001; Franz et al., 2008),
adults with SUDs—both abstinent and undergoing treatment—
show higher percentages. Despite a first overestimation of 78%
(Rybakowski et al., 1988), the prevalence is typically estimated
in the range of 43.5 to 67% (Taylor et al., 1990; Haviland
et al., 1994; Farges et al., 2004; Speranza et al., 2004; Oyefeso
et al., 2008; Lindsay and Ciarrochi, 2009; Thorberg et al.,
2009), even though a recent review asserts that it is about 30–
49% (Cruise, 2017). Differences in alexithymia rates can be
explained by looking at the assessment methods applied and
sample characteristics, including the severity of the disorder, the
type of treatment (outpatient or inpatient), and the substance
being abused (alcohol, opioids, etc.,). Also, when alexithymia
is measured as a continuous variable, individuals with SUDs
show higher alexithymia traits (Handelsman et al., 2000; Cleland
et al., 2005; Ghalehban and Besharat, 2011; Lyvers et al., 2012;
Torrado et al., 2013; Nehra et al., 2014). Difficulties in identifying
and expressing emotions are also related to increased drug use
among adolescents (Trinidad and Johnson, 2002), and using
cut-off scores, alexithymia prevalence among young substance
abusers (aged 14–25) is noteworthy, ranging from 35 to 43%
(Troisi et al., 1998; Farges et al., 2004; Dorard et al., 2008a,b,
2017; Parolin et al., 2017). Studies have used the self-report
TAS-20 and almost exclusively address outpatient youth with
cannabis use disorders (including both abuse and dependence),
with only two exceptions. The study by Farges et al. (2004) did
not specify the substance, and in the study by Parolin et al. (2017),
a majority of the inpatient participants were opioid dependent.
Despite rates among young substance users seeming higher than
that among the general population of youth (Säkkinen et al.,
2007), when young substance users and controls were compared,
the difference in prevalence did not reach statistical significance
(Dorard et al., 2008b).
The relationship between alexithymia and addiction is
supported by a significant positive association between
alexithymic traits and craving, the severity of the disorders
and related difficulties (Cleland et al., 2005; Thorberg et al., 2010,
2011a,b). It has been hypothesized that alexithymia may be a
vulnerability factor that predates SUDs (Taylor et al., 1997; De
Rick and Vanheule, 2006; de Timary et al., 2008). As suggested
by Taylor et al. (1997), the role of alexithymia as risk factor for
SUDs may be explained by taking into account inherent aspects
of the construct (such as immature self-awareness and scarce
cognitive regulation of one’s emotions). Alternatively, it can be
the result of interactions with other risk factors, such as drug
expectations, negative affectivity, insecure attachment, executive
function, and personality disorders (Pinard et al., 1996; Lumley,
2000; Thorberg et al., 2009; Lyvers et al., 2012; De Carli et al.,
2016). Despite some data on clinical (Cecero and Holmstrom,
1997; Uzun, 2003) and non-clinical populations (Kauhanen et al.,
1992; Bruce et al., 2012) confirming the theoretical assumption
suggesting that alexithymia is a risk factor in the genesis of
SUDs, questions remain, and empirical evidence is scarce and
non-univocal, as reported by Thorberg et al. (2009) in a review
study. Moreover, alexithymia may be a predisposition factor
for psychiatric disorders others than drug addiction (Taylor
et al., 1997), thus calling the specificity of the association with
SUDs into question. Thus, the relationship between alexithymia
and drug dependence remains quite unclear (Teixeira, 2017);
alexithymia might be a consequence or correlate of the drug
disorder (Thorberg et al., 2009).
In alexithymia research, the TAS-20 is the most widely
used and studied measure (Taylor et al., 2003; Meganck et al.,
2008). Several studies have adopted the TAS-20 to investigate
alexithymia in patients with SUDs (Haviland et al., 1988c, 1994;
Taylor et al., 1990; Haviland, 1996), reporting rates of 42–50%,
thus higher than non-clinical (4–18%) and psychiatric groups
(12–33%) (Handelsman et al., 2000; Taylor, 2000). The TAS-20
can discriminate well between psychiatric young patients and
non-clinical youth (Kooiman et al., 2002; Marchesi et al., 2014).
Despite its worldwide use in research and clinical practice,
the TAS-20 has been criticized for some shortcomings: a critical
review of the literature revealed the insufficient reliability of
its third subscale (“Externally oriented thinking”), showed the
presence of different factor structures in various patient samples
and underlined a lack of studies on its criterion validity (Kooiman
et al., 2002). As a matter of fact, there are significant relationships
between alexithymia, as measured by the TAS-20, and negative
affects, depression, and anxiety in both non-clinical (Honkalampi
et al., 2010; Deno et al., 2011) and clinical samples (Marchesi
et al., 2000; Gatta et al., 2016), including patients with SUDs
(Haviland et al., 1988a,b, 1991, 1994; Taylor et al., 1990; Farges
et al., 2004; de Haan et al., 2011, 2012a; Morie et al., 2015). In
order to examine if the TAS-20 measures the broader construct
of negative affects rather than identifying alexithymia itself in
clinical groups, Marchesi et al. (2014) compared patients with
different diagnoses (major depression, panic disorder, eating
disorder, and SUD) to controls. The results indicated that all
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clinical groups showed higher TAS-20 scores than the controls
but not when controlling for anxiety and depression, suggesting
that alexithymia as measured by the TAS-20 may have an issue
with discriminant validity.
This leads to a more general limitation concerning the
assessment of alexithymia with self-report measures, which can
be called into question, since they require respondents to report
on their psychological states, yet alexithymic individuals lack this
capacity by definition (Lane et al., 1997; Lumley, 2000;Waller and
Scheidt, 2004). In the specific case of SUDs, substance abusers
self-reported higher alexithymia on the TAS-20 than controls
and patients with other psychiatric disorders, but their actual
performance on a task that required them to identify and describe
feelings was not significantly different (Lindsay and Ciarrochi,
2009). As the authors of the instrument acknowledged (Taylor
et al., 1997), a multi-method approach is recommended to assess
alexithymia: the TAS-20 could be used in combination with
other-report instruments (Kooiman et al., 2002). Unfortunately,
to date, few studies have compared different measures, especially
in the field of addiction. The Observer Alexithymia Scale (OAS;
Haviland et al., 2000) represents an alternative assessment
measure. The OAS has been used in studies on substance abusers,
both adults and adolescents, together with the TAS-20 (Dorard
et al., 2008a; Thorberg et al., 2010, 2013; Parolin et al., 2017).
It demonstrated adequate psychometric properties and rather
low correlations with the TAS-20 total scores and subscales,
indicating a lack of correspondence between the two measures
(Dorard et al., 2008a).
Alexithymia as Predictor of Treatment
Outcomes
Since alexithymia is a well-recognized and clinically relevant
concept, studies have examined whether alexithymic traits may
have implications for how drug-dependent patients respond
to treatment, but the empirical evidence is non-univocal.
Alexithymia (encompassing low self-awareness and interest in
introspective activities, scarce empathy and emotion regulation,
high negative affectivity and impulsivity and non-optimal
coping strategies) may impede treatment and facilitate the use
of substances in case of heightened distress (Bagby et al.,
1993; Parker et al., 1998; Oyefeso et al., 2008; Shishido
et al., 2013). Some evidence has attested that alexithymia may
interfere with treatment success. As regards relapse, a cross-
sectional investigation on outpatients with alcohol use disorder
(Ziółkowski et al., 1995) found significant differences in total
scores and alexithymia rates between long abstainers ( > 1 year)
(33% of alexithymics) and short abstainers ( < 1 year) (63%
of alexithymics); stepwise multiple linear regression analysis
indicated that the overall TAS-20 score accounted for 20% of the
variation in abstinence. Similarly, in a cohort of outpatients with
alcohol use disorders, Loas et al. (1997) found significantly higher
levels of alexithymia at treatment intake among outpatients
who relapsed at 15-month follow-up, even after controlling
for depression. The TAS-20 factor accounted for 17% of the
variance in abstinence, indicating that alexithymia can predict
higher risk of relapse. Alexithymia may also predict treatment
engagement, in terms of session attendance and working alliance
(drug-dependent outpatients who were higher in alexithymia
attended fewer sessions and formed weaker alliances) (Cleland
et al., 2005). In studies on inpatients with alcohol use disorder
(de Haan et al., 2012b), baseline alexithymia showed no relation
to abstinence, time in treatment or changes in disorder severity
at 1-year follow-up. Similarly, as concerns SUDs ( de Haan
et al., 2011), alexithymia (measured as both a continuous and
a categorical variable) was not related to abstinence, and high-
scoring alexithymics did not differ from low-scoring alexithymics
in mean time in treatment or dropout rates (50 vs. 43%).
A prospective study on alcoholics (Junghanns et al., 2005)
found that alexithymia scores were not associated with the
risk of relapse at 6-week follow-up. A recent study confirmed
that alexithymia was not strongly associated with treatment
adherence or retention in an 8-week randomized clinical trial
(Morie et al., 2015). Thus, empirical evidence on the relationship
between alexithymia and treatment outcome in SUDs is limited
and non-univocal. Substance use treatment is hindered by high
rates of relapse (60–70%) (Bradizza et al., 2006) and premature
termination, to the extent that it is more common for a patient to
drop out of addiction treatment than to complete the treatment
(Stark, 1992; Brorson et al., 2013). On the contrary, completion
of addiction treatment is one of the most consistent factors
associated with a favorable treatment outcome (Hser et al.,
2004). This implies the importance of identifying predictors of
treatment retention and adherence.
Alexithymia has been recognized as being associated with
several psychiatric disorders, including chronic pain. The
mediation of pain intensity by prescription painkiller use suggests
a process in which more intense pain leads to more frequent use
of stronger (prescription) painkillers, which increases the risk of
dependence (Elander et al., 2014). The self-medicating hypothesis
proposes that individuals use substances to cope with negative
affects (Ghalehban and Besharat, 2011). Because of their cognitive
inability to identify their emotions, alexithymic individuals may
use drugs to regulate their emotions and alleviate stress (Shorin,
1998). Thus, it is difficult to determine whether alexithymia
is a specific characteristic of SUDs. These doubts increase in
light of the controversy over how to assess the construct to
discriminate between primary and secondary alexithymia and
related outcomes. Since some evidence has raised concerns on
the TAS-20’s discriminant validity, a multimethod assessment
could spread light on this debate. In addition, little research has
addressed this issue in adolescents. Finally, it is not clear whether
alexithymia can be considered a risk factor for negative treatment
outcomes.
Objectives
The aim of the present study is to investigate alexithymia
in substance-dependent young adults, focusing on some
methodological issues. In particular, we are interested in
examining whether the available and commonly used assessment
measures (self-report and observational) are suitable for
evaluating alexithymia in SUD populations. We examine this
issue by investigating two objectives: (a) the specificity of
alexithymia in drug-dependent inpatients, compared to healthy
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individuals and patients with psychiatric disorders, and (b) the
predictivity of alexithymia in determining treatment outcomes in
terms of relapses, drop-outs from treatment and rates of relapse
per month of treatment. To fulfill these aims, two studies were
conducted, referred to as Study 1 (a) and Study 2 (b).
Study 1 investigates whether young adults diagnosed with
SUDs differ from referred psychiatric outpatients and controls in
terms of alexithymia levels, as measured by the TAS-20. Based
on previous literature, we hypothesized that drug-dependent and
referred youths would show higher levels of alexithymia than
controls.
Study 2 focuses on a group of inpatients with SUDs and
addresses two questions. First, we investigated whether self-
report and observational measures differ in their evaluation
of alexithymia. According to previous studies, our hypothesis
proposes a lack of correspondence between self-report and
observational measures, in light of the doubts regarding the
validity of self-report tools in assessing alexithymia in clinical
samples. Second, Study 2 investigated the ability of alexithymia
to predict treatment outcomes. Based on the relevance ascribed
to alexithymia in clinical practice and recognizing the lack of
consensus on the association between alexithymia and SUD
treatment outcomes, we were interested in the predictive role
of observed and self-reported alexithymia (at the baseline) for
treatment response 1 year after admission, in terms of relapses,
dropouts from treatment and rates of relapse per month of
treatment. We hypothesized that alexithymia (implying poor
introspective capacity, high negative affectivity and non-optimal
coping) can predict higher risk of relapse and dropout from
treatment. A negative relationship with treatment success would
support the need to specifically address alexithymia and adjust
treatment protocols.
STUDY 1
Materials and Methods
Participants
Study 1 involved 90 late adolescents, aged 17–21, who comprised
two clinical groups and a comparison group Table 1. The
clinical groups included 30 inpatients diagnosed with SUDs and
admitted to a residential treatment facility (SUD group) and 30
late adolescents referred to an outpatient neuropsychiatric unit
(clinically referred group).
The SUD group included 30 young inpatients admitted to
a therapeutic community for SUDs (Villa Renata, Comunità di
Venezia, Venice, Italy) and met the following inclusion criteria:
(a) diagnosed with SUD according to DSM-5 (APA, 2013)
criteria; (b) referred and admitted to the residential treatment
community for less than 3 months; and (c) age ranging from 17
to 21 years.
A cohort of 30 patients referred to the Mental Health Public
Service (SCIAF ULSS 6, Padua, Italy) for psychopathological
problems was recruited. The inclusion criteria were: age between
17 and 21 years, a diagnosis classification of “behavioral and
emotional disorders with onset usually occurring in childhood
and adolescence” (F90-F98) or “affective [mood] disorders”
(F30-F39) (according to ICD-10; World Health Organization,
2016), and no mental delay (QI > 70, according to Wechsler,
2003).
The comparison group included 30 healthy young adults,
recruited in high schools near Venice, Italy. The main selection
criteria used in the data collection were: (a) the absence of
psychiatric disorder diagnosis; (b) absence of current drug use;
and (c) age between 17 and 21 years.
Procedure and Instruments
This first study was carried out in accordance with the
recommendations of the Code of Ethics approved by the General
Assembly of the Italian Association as well as the Ethical
Committee of University of Padua (protocol reference number:
2038). All of the subjects provided written informed consent
(parental, in the case of minors) to participate to the study.
All of the participants completed the TAS-20 and the SCL-
90-R; for the two clinical groups, administration occurred at
treatment intake, as part of an assessment protocol.
- The 20-item Toronto Alexithymia Scale (TAS-20; Bressi et al.,
1996). Developed by Bagby et al. (1994a,b), the TAS-20 is a
self-report scale made of 20 items that must be rated from
1 (strongly disagree) to 5 (strongly agree); the sum of the
items generates a total score and scores for three subscales.
The scale has a three-interrelated-factor solution: difficulty
identifying feelings (F1), difficulty describing feelings (F2),
and externally oriented thinking (F3). Although predominantly
used as a dimensional construct, the total score can be
compared to cut-off scores that categorize respondents into
alexithymic (≥ 60), borderline/intermediate (≤ 51 and ≥
60) and non-alexithymic. The scale was evaluated as a
reliable and valid measure in non-clinical and clinical samples
(Parker et al., 1993, 2003; Bagby et al., 1994a,b; Bressi
et al., 1996; Taylor et al., 2003), even though the TAS-
20 has shown some psychometric shortcomings (Kooiman
et al., 2002). The reliability and factor solution of the TAS-
20 in samples of substance abusers have been tested and
shown sufficiently good results, with the only exception being
the Externally Oriented Thinking subscale (Haviland et al.,
1988c; Cleland et al., 2005). Moreover, an Italian study
conducted on adolescents (La Ferlita et al., 2007) only partially
replicated the original factor structure of the TAS-20 and
showed higher levels of alexithymic traits in comparison to
adults.
- The Symptom Checklist-90-Revised (SCL-90-R; Derogatis,
1994). The SCL-90-R is a self-report measure assessing 90
clinical symptoms on a 5-point Likert scale, ranging from
0 (not at all) to 4 (extremely). The symptoms are factored
into nine psychiatric dimensions (depression, anxiety,
somatization, obsessive-compulsive behavior, interpersonal
sensitivity, hostility, phobic anxiety, psychoticism, and
paranoid ideation) plus altered appetite and disturbed sleep.
The instrument provides three global scores: the global stress
index (GSI), the positive symptom total (PST) and the positive
symptom distress index (PSDI). Both the original version
and the Italian translation (Sarno et al., 2011) show adequate
psychometric properties (Derogatis, 2011). The present study
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TABLE 1 | Descriptive characteristics of each group.
Sud group Clinical groups Healty group
M SD M SD M SD
Age 19.40 1.25 17.93 1.44 18.70 1.24
N (%) N (%) N (%)
Male 16 (53) 16 (47) 12 (40)
Female 14 (46) 14 (53) 18 (60)
Poli-abusers (90)
Heroin as primary drug of abuse (63)
is based on the SCL-90-R, since it can distinguish between
clinical and non-clinical individuals via the cut-off score of the
GSI.
Plan of Analysis
First, the TAS-20 scale scores were compared between the
substance-dependent, referred clinical sample, and non-clinical
control groups. One ANOVA model was computed for each
TAS-20 subscale, controlling for participants’ gender and age.
Then, partial correlations between alexithymia and depressive
symptomatology were computed, controlling for gender and age.
Results
Figure 1 shows the differences in TAS-20 scores between
the groups. Controlling for age and gender, the effect of
group was significant for Difficulty in Describing Feelings
[F(2,85) = 3.19, p = 0.046, ηp
2
= 0.08], Difficulty Identifying
Feelings [F(2,85) = 5.17, p = 0.008, ηp
2
= .11], and Global Scale
[F(2,85) = 5.14, p = 0.008, ηp
2
= 0.11] but not for Externally
Oriented Thinking [F(2,85) = 2.84, p= 0.06, ηp
2
= 0.05]. Two out
of three significant results remained unaltered after Bonferroni
correction for multiple comparisons (significance threshold, p <
0.013). The Difficulty in Describing Feelings scale did not survive
the correction for multiple comparison. Post hoc comparison
(Tukey contrasts) showed that the substance-dependent and
non-clinical control groups differed on the Difficulty Describing
Feelings scale (b = 4.13, 95% CI [0.58; 7.69], p = 0.02), but
there was no difference between the substance-dependent and
referred patient groups (b = −0.63, 95% CI [−4.19; 2.92],
p = 0.91) as well as between non clinical controls and referred
patients (b = 3.50, 95% CI [−0.06; 7.06], p = 0.06). For
Difficulty Identifying Feeling, only the referred patient group
FIGURE 1 | TAS-20 differences between groups.*p < 0.05; **p < 0.01.
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differed from the control group (b = 3.73, 95% CI [1.06;
6.41], p = 0.004) because there was no difference between the
substance-dependent group and both the control (b = 2.57, 95%
CI [−0.11; 5.24], p= 0.06) and referred patient groups (b= 1.17,
95% CI [−1.51; 3.84], p = 0.55). Finally, for the Global Scale,
we found significant differences when comparing the substance-
dependent (b = 2.51, 95% CI 0.21; 4.81], p = 0.03) and referred
patient groups (b = 3.29, 95% CI 0.99; 5.59], p = 0.003) with the
control groups, but no differences between them (b = 0.78, 95%
CI [−1.52; 3.08], p= 0.70).
In the global sample, the partial correlation between
alexithymia and depression, as measured by the SCL-90-R and
controlling for gender and age, was r(88) = 0.45, p < 0.001.
The correlation was essentially the same in the substance abusers
group, r(28) = 0.44, p= 0.01.
STUDY 2
Materials and Methods
Participants
A total of 55 inpatients with SUD were involved in Study 2;
in addition to those who participated to Study 1 (N = 30), 25
additional participants were included.
Inpatients were recruited from a therapeutic community
(Villa Renata, Comunità di Venezia, Venice, Italy). The
therapeutic community treatment model (De Leon et al., 2015),
is based on a long-term residential and intensive approach
that combines therapeutic and educational activities. Inpatients
attend daily occupational, house-service, and recreational
activities together with staff members, who offer monitoring and
support to foster self-help learning. Weekly individual and group
psychotherapy is provided, with the primary goal of changing
the negative patterns of behavior, thinking, and feeling that
predispose the individual to drug use as well as developing
interpersonal skills and psychological wellbeing.
The participants (described in Table 2) fulfilled the following
inclusion criteria: (a) met the DSM-5 (APA, 2013) criteria for
SUD; (b) referred and admitted to the residential treatment
community for less than 3 months; and (c) age ranging from 17
to 24 years. At recruitment, the participants had been abstinent
for 2.83 months on average. Additionally, 46% overdosed from
one to three times in the past, and 21% had a drug-related
illness (hepatitis C). In relation to treatment, 40% of participants
had previously attended an inpatient treatment but had not
concluded it. At 1 year after admission, 49% of the participants
dropped out from treatment, while 59% relapsed during the 12
months of treatment. These data are in line with previous studies,
reporting dropout rates of 17–57% for residential treatment
(Brorson et al., 2013) and relapse rates of 40–60% (McLellan et al.,
2000).
Procedure and Instruments
This second study was carried out in accordance with the
recommendations of the Code of Ethics approved by the General
Assembly of the Italian Association as well as the Ethical
Committee of University of Padua (protocol reference number:
2038). All patients provided written informed consent (parental,
in the case of minors) to participate to the study.
The participants of Study 2 completed the TAS-20 at
admission, and their individual treating psychologists completed
the OAS after 8 to 12 weeks of treatment. After 1 year of
residential treatment, or after dropout, the number of relapses
was reported from the community registers.
- The Observer Alexithymia Scale (OAS; Haviland et al., 2000).
The OAS is a 33-item observational scale to be completed
by a subject’s relative or acquaintance. The instrument was
developed by asking clinicians to describe the prototypical
characteristics of an alexithymic person. Items are rated on
a 4-point scale and cover five alexithymic features: distant
(being unskilled in intrapersonal and interpersonal issues),
uninsightful, somatizing, humorless, and rigid. The reliability
and validity of the OAS have been tested in both non-clinical
(Haviland et al., 2000) and clinical samples (Haviland et al.,
TABLE 2 | Descriptive characteristics of SUD group.
INPATIENTS SUD GROUP
Age Age M SD
21.10 2.15
N (%)
Gender Male 30 (54%)
Female 25 (45%)
SES Not attained an upper secondary educational qualification 33 (60%)
Unemployed 35 (63%)
Past history Had one or both parents presenting a past or current Substance Use Disorder 24 (43%)
Experienced maltreatment, sexual or physical abuse during childhood 34 (61%)
Comorbidities Psychiatric illness 16 (29%)
Poly-drug use Poly-drug use 47 (86%)
Primary substance of abuse Different synthetic drugs 46 (83%)
Cocaine 10 (18%)
Heroin 38 (69%)
Use of non-prescribed drugs 29 (53 %)
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2001; Thorberg et al., 2010). Adequate internal consistency,
test-retest reliability and factorial validity emerged; moreover,
total OAS scores differed significantly between the clinical
and non-clinical groups (Haviland et al., 2001). Despite
these results and its clinical utility, the OAS presents
some limitations: some researchers (Meganck et al., 2010)
have questioned its validity because of insufficient interrater
reliability and problematic criterion validity (it seems that the
OAS is based on a broader definition of alexithymia than the
original one, including some characteristics that are correlates
of alexithymia rather than constitutive dimensions).
Plan of Analysis
In different regression models controlling for gender and age,
both self-report and observational measures of alexithymia were
used as predictors for the number of relapses, number of
dropouts from treatment, and the rates of relapse per month of
treatment. We used the ratio between the number of relapses to
months of treatment due to the high incidence of dropouts, which
made the absolute number of relapses a potentially biased effect
depending on the length of the hospitalization. Next, gender
was added as a possible moderator of the association between
alexithymia and outcome measures.
Results
Table 3 shows the partial correlations between observed and self-
reported alexithymia after controlling for gender and age.Table 4
presents all of the linear and logistic regression models used to
test the role of alexithymia (both self-reported and observed) in
predicting relapses and dropouts. For each model, the interaction
effect gender∗alexithymia is also provided. Since the interactions
between gender and two scales of the OAS were significant in
predicting the rate of dropouts per months of treatment, we
computed simple slope analyses to explore these results, which
are plotted in Figure 2. The effects of the OAS total score scale
were positive and significant for males [b = 0.01, SE = 0.005,
t(44) = 2.15, p= 0.04] but not significant for females [b=−0.006,
SE= 0.003, t(44) =−1.73, p= 0.09]. Indeed, the same effect was
found for the Distant scale, which was significant and positive
for males [b = 0.03, SE = 0.01, t(44) = 2.60, p = 0.01] but not
significant for females [b = −0.01, SE = 0.01, t(44) = −1.04,
p= 0.30].
DISCUSSION
The present study contributes to the current debate on
alexithymia, specifically concerning two controversial aspects: its
associations with SUDs (i.e., in terms of prevalence and treatment
predictivity) and some assessment issues, since the TAS-20 has
received criticism, despite its worldwide use and validity.
Specificity of Alexithymia in
Drug-Dependent Young Adults
The aim of Study 1 was to investigate whether late adolescents
diagnosed with SUDs differ from late adolescent referred
psychiatric outpatients and controls in levels of alexithymia, as
measured by the TAS-20. On the basis of previous literature
attesting that the TAS-20 can discriminate well between
psychiatric patients and non-clinical youths (Kooiman et al.,
2002; Marchesi et al., 2014), we hypothesized that drug-
dependent and referred youth would show higher levels of
alexithymia than controls. The results indicated that patients
in both clinical groups, regardless of their specific disorder,
presented higher TAS-20 scores than non-clinical subjects, but
the clinical groups did not differ from each other. In considering
the lack of difference between the two clinical groups, it is
important to acknowledge that SUD populations show high
rates of comorbidity and that our study only relied on the
SCL-90-R. Our data resemble those of Marchesi et al. (2014),
who compared different groups of adult patients (with major
depression, panic disorder, eating disorder, and SUDs) and
controls. Thus, despite numerous studies suggesting the presence
of a specific link between alexithymia and addiction (i.e., as a
risk factor), alexithymia might be non-univocally related to SUD
nor to other distinct disorders. Instead, it could be associated
with the broader concept of psychological distress, regardless
of the symptomatological phenomenology. Consistent with this
idea, Study 1 highlighted a large correlation between alexithymia
and depressive symptoms. A vast body of literature shows that
alexithymia is positively related to psychological distress in
general and depressive and anxiety symptomatology (Haviland
et al., 1991), and this association has also been detected when
adopting the TAS-20 in non-clinical (Honkalampi et al., 2010;
Deno et al., 2011), clinical (Marchesi et al., 2000) and SUD groups
(Haviland et al., 1988a, 1991, 1994; Taylor et al., 1990; de Haan
et al., 2011, 2012a;Morie et al., 2015). Recently, empirical support
has been given to the notion that alexithymia, as measured by
the TAS-20, may represent an issue with discriminant validity
(Marchesi et al., 2014) and that the TAS-20 assesses a general
psychological distress factor rather than identifying alexithymia
itself (Leising et al., 2009).
Predictivity of Self-Report and Observed
Alexithymia
Study 2 focused on a group of young adults diagnosed with
SUD. First, it examined whether self-report and observational
measures differ in the evaluation of alexithymia. Despite a wide
consensus on the need to use a multi-method approach to assess
alexithymia, such an approach is rarely achieved (Kooiman et al.,
2002). In the present sample, clinician-rated alexithymia (by the
OAS) was not correlated with self-report alexithymia (by TAS-
20); our results are consistent with those of a previous study
on adolescent substance-abusers that compared OAS and TAS-
20 scores and indicated a lack of correspondence between the
scores of the two assessment tools (Dorard et al., 2008a). As a
whole, the adequacy of the TAS-20 in assessing alexithymia, as
with other self-reports, appears to be questionable. This might
particularly be the case for clinical groups characterized by low
levels of self-reflective capacity, including such individuals with
SUDs.
Contrary to expectations, neither self-reported nor observed
alexithymia predicted the number of relapses, retention or
dropout from treatment. Our results are in line with those
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TABLE 3 | Partial correlations between self-reported and observed alexithymia measures controlling for gender and age.
1 2 3 4 5 6 7 8 9 10
Difficulty identifying feelings (F1)
Difficulty describing feelings (F2) 0.58***
Externally Oriented Thinking (F3) 0.30* 0.38***
TAS 20 Total 0.86*** 0.83*** 0.64***
Distant −0.05 −0.09 0.14 −0.02
Uninsightful 0.24† 0.07 −0.01 0.15 0.37**
Somatiazing −0.01 −0.15 −0.07 −0.09 0.14 0.18
Humorless −0.01 0.13 0.26† 0.13 0.31* 0.43*** 0.19
Rigid −0.33* −0.11 −0.15 −0.27* 0.24† 0.26* 0.17 0.32*
OAS Total −0.01 −0.06 0.04 −0.02 0.72*** 0.75*** 0.5*** 0.61*** 0.57***
***p < 0.001; **p < 0.01; *p < 0.05;
†
p < 0.1.
of other empirical works indicating the lack of an association
between alexithymia and abstinence, time in treatment and
treatment adherence (Junghanns et al., 2005; de Haan et al., 2011,
2012b; Morie et al., 2015).
Different possible explanations can be given for these results.
One explanation looks at alexithymia, its stability and its role as a
vulnerability factor. As noted by deHaan and colleagues (deHaan
et al., 2012a, 2014), alexithymia can be a vulnerability factor for
substance use (and thus be reasonably addressed in treatment)
only if it is a stable personality trait, but research results are
conflicting regarding the stability of alexithymia. Studies support
the idea that alexithymia is (at least partially) a state-related
phenomenon (de Haan et al., 2012a, 2014). It has been conceived
of as a secondary and situational response to negative affectivity,
anxiety and depression (Haviland et al., 1988a; Pinard et al., 1996;
Taylor et al., 1997; Honkalampi et al., 2000; de Timary et al., 2008;
De Carli et al., 2017). Moreover, studies supporting the view of
alexithymia as a structural trait in substance-dependent patients
consider quite limited periods of time (Keller et al., 1995; Pinard
et al., 1996; Rosenblum et al., 2005) or demonstrate its relative
but not its absolute stability (de Timary et al., 2008; Thorberg
et al., 2016). The state-dependent nature of alexithymia in drug-
dependent individuals could explain why alexithymia measured
at treatment intake is unrelated to events occurring later (by up
to 1 year).
Second, in accordance to other authors (Cleland et al.,
2005; Junghanns et al., 2005), the limited predictive capacity
of alexithymia may depend on the fact that alexithymia may
influence treatment outcomes only when interacting with other
factors, such as negative affectivity, anxiety or depressive
symptoms. Maybe the availability of more detailed measures of
time (including when relapses and treatment dropouts occur),
concurrent levels of alexithymia and negative affectivity could
help to clarify the relation between alexithymia and treatment
indexes.
Third, the lack of association can be explained by the fact
that dropout and relapse might depend on different and/or
multiple factors, rather than single variables. To date, there is a
general lack of consistency in these predictors across studies. A
number of factors have shown no or minimal predictivity for
treatment retention, including demographic variables (gender,
socioeconomic status, employment, and education). The most
consistent risk factors for dropout include cognitive deficits, weak
treatment alliance, personality disorders, younger age (Brorson
et al., 2013), and client motivation (Ball et al., 2006; Palmer et al.,
2009). Regarding relapses, investigators have identified some
risk factors, like severity of SUD and its sequelae, psychiatric
comorbidity, family history of SUDs, stressors, and coping.
Importantly, the most reliable predictive models of relapses and
dropout take into account a multitude of predictors and their
interactions (Bradizza et al., 2006;Moos andMoos, 2006; Brorson
et al., 2013; Brecht and Herbeck, 2014).
Finally, methodological issues regarding the assessment
measures, sample characteristics, and type of treatment have
been pointed to the lack of a strong association between
alexithymia and outcomes (Cleland et al., 2005). Regarding
treatment, alexithymia may exert a different degree of influence
on treatment success by treatment approach (de Haan et al.,
2012b; Morie et al., 2015). However, the available results
are highly preliminary and limited; thus, conclusions on the
relationship between alexithymia and treatment type cannot be
drawn.
At an exploratory level, we tested the moderating role of
gender on the association between alexithymia and treatment
outcomes. The interaction effects between gender and two of the
subscales for observed alexithymia were significant. Specifically,
the global score and the Distant factor predicted the number
of relapses in males but not in females. The effect of the
global score seems to be driven by the Distant subscale. This
factor describes an avoidant style toward relationships and inner
states, and probably toward the treatment alliance too. Due
to the explorative nature of the investigation, interpretations
should be made extremely carefully. However, future studies
could focus on the relevance of avoidant behaviors between
males but not females in the quality of treatment outcomes.
It is possible that the presence of avoidant strategies is more
risky for men than for women, probably because it could be
more closely related to impulsive behaviors. Such a finding,
even if presented for the first time, has similar results in
previous literature, such as a moderating effect of gender in
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FIGURE 2 | Simple slope analyses of the effects of 2 OAS scales (i.e, Distant and Total) on the rate of relapses per month.
the association between hostility and treatment termination
(Petry and Bickel, 2000). The study of moderators of risk
factors for treatment dropout is extremely relevant to foster
tailored interventions (Brorson et al., 2013) and deserves future
attention.
In conclusion, the present study suggests that alexithymia,
as measured by the TAS-20, does not distinguish young
inpatients with SUDs from referred patients and controls—
it only differentiates between clinical and non-clinical groups.
As recent empirical studies have proposed, alexithymia might
be more associated with negative affectivity or psychological
distress, rather than characterizing distinct disorders. These
results, together with the lack of correspondence between the
TAS-20 and the OAS observational scale, raise doubts on the
validity of alexithymia being measured by self-reports. Finally,
the limited ability of both observed and self-reported measures
in predicting treatment dropout and relapses highlights the need
for more complex predictive models in treatment research.
Despite some strengths, such as the multi-method assessment
of alexithymia, addressing substance abuse at a specific age
(young adulthood) and adopting a wide window of time (1
year), the research shows some limitations. First of all, the
relatively small samples involved suggest caution in interpreting
the results, particularly the lack of effects of alexithymia in
predicting treatment outcomes. In addition, the prediction
of outcomes was limited to 1 year of treatment, meaning
that no inferences can be made on long-term results of the
intervention. In addition, no assessment of symptom severity
was available. Furthermore, the lack of systematic biochemical
analyses to confirm abstinence/relapses must be acknowledged.
Also, with regard to the comparison group of referred patients
in Study 1, the participants were not affected by a specific
psychiatric disorder but presented heterogeneous diagnoses.
Another difference with the SUD group was the condition of
being outpatients, instead of inpatients, which is likely to be
associated with diminished illness severity. In addition, observed
alexithymia was not assessed in the nonclinical or referred
samples, since it was not possible to identify observers who
were comparable to the therapists for the SUD group. Finally, as
already mentioned, the predictivity of alexithymia was analyzed
by taking single factors into consideration, rather than multiple
variables.
Future studies should try to extend the observational measure
of alexithymia to other disorders to explore whether the lack
of correlation with the TAS-20 is specific to SUDs. In addition,
future perspectives could try to replicate the moderating effect
of gender on the association between alexithymia and treatment
outcome. Also, not only can observers’ ratings of alexithymia
improve our understanding of the concept, but so can integration
with other fields of study, such as family functioning (Gatta
et al., 2017), endocrine functioning (Riem et al., 2017), and
brain activity (De Carli et al., 2018).
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